Gold-facilitated in Situ Hybridization: a Bright-field Autometallographic Alternative to Fluorescence in Situ Hybridization for Detection of Her-2/neu Gene Amplification

Overview

Journal Am J Pathol

Publisher Elsevier

Specialty Pathology

Date 2002 May 10

PMID 12000711

Citations 7

Authors

Raymond Tubbs

James Pettay

Marek Skacel

Richard Powell

Mark Stoler

Patrick Roche

James Hainfeld

Affiliations

Soon will be listed here.

Abstract

Fluorescence in situ hybridization (FISH) represents an excellent method for profiling gene amplification in situ, but correlation with tissue morphology is difficult because of dark-field visualization. Validation of a bright-field assay for assessment of HER-2/neu gene amplification was investigated. Streptavidin-Nanogold was used to generate bright-field gene copy signals using GoldEnhance gold-based autometallography, catalyzed reported deposition, and a biotin-labeled probe. One hundred cases of invasive breast carcinoma were evaluated for which FISH gene copy results, and mRNA and oncoprotein gene expression, were known. Autometallographic signals were qualitatively evaluable without the use of oil immersion microscopy. Results correlated well with indirect and direct label FISH. Autometallographic gold-based in situ hybridization represents a promising bright-field assay for the assessment of HER-2/neu gene amplification.

Citing Articles

Testing for HER2 in Breast Cancer: A Continuing Evolution.

Shah S, Chen B Patholog Res Int. 2010; 2011:903202.

PMID: 21188214 PMC: 3005907. DOI: 10.4061/2011/903202.

Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma.

Gruver A, Peerwani Z, Tubbs R J Clin Pathol. 2010; 63(3):210-9.

PMID: 20203220 PMC: 2921277. DOI: 10.1136/jcp.2009.062760.

Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ....

Nitta H, Hauss-Wegrzyniak B, Lehrkamp M, Murillo A, Gaire F, Farrell M Diagn Pathol. 2008; 3:41.

PMID: 18945356 PMC: 2577627. DOI: 10.1186/1746-1596-3-41.

Genotyping of phenotypically defined cells in neoplasia: enhanced immunoFISH via tyramide signal amplification (TSA) segregates immunophenotypically-defined cell populations for gated genotyping.

Tubbs R, Das K, Cook J, Pettay J, Roche P, Grogan T J Mol Histol. 2007; 38(2):129-34.

PMID: 17205377 DOI: 10.1007/s10735-006-9074-1.

Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer.

Hauser-Kronberger C, Dandachi N J Mol Histol. 2004; 35(6):647-53.

PMID: 15614619 DOI: 10.1007/s10735-004-2186-6.

References

Roche P, Ingle J . Increased HER2 with U.S. Food and Drug Administration-approved antibody. J Clin Oncol. 1999; 17(1):434. DOI: 10.1200/JCO.1999.17.1.434. View

Gusterson B, Gelber R, Goldhirsch A, Price K, Anbazhagan R, Styles J . Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol. 1992; 10(7):1049-56. DOI: 10.1200/JCO.1992.10.7.1049. View

Seshadri R, Firgaira F, Horsfall D, McCaul K, Setlur V, Kitchen P . Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol. 1993; 11(10):1936-42. DOI: 10.1200/JCO.1993.11.10.1936. View

Kakar S, Puangsuvan N, Stevens J, Serenas R, Mangan G, Sahai S . HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival. Mol Diagn. 2000; 5(3):199-207. DOI: 10.1054/modi.2000.16690. View

Ridolfi R, Jamehdor M, Arber J . HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol. 2000; 13(8):866-73. DOI: 10.1038/modpathol.3880154. View

Toikkanen S, Helin H, Isola J, Joensuu H . Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol. 1992; 10(7):1044-8. DOI: 10.1200/JCO.1992.10.7.1044. View

Press M, Hung G, Godolphin W, Slamon D . Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 1994; 54(10):2771-7. View

Graf A, Cheung A, Dandachi N, Tubbs R, Dietze O, Hacker G . Clinical relevance of HPV 16/18 testing methods in cervical squamous cell carcinoma. Appl Immunohistochem Mol Morphol. 2000; 8(4):300-9. View

Hoang M, Sahin A, Ordonez N, Sneige N . HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol. 2000; 113(6):852-9. DOI: 10.1309/VACP-VLQA-G9DX-VUDF. View

10.

Cobleigh M, Vogel C, Tripathy D, Robert N, Scholl S, Fehrenbacher L . Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999; 17(9):2639-48. DOI: 10.1200/JCO.1999.17.9.2639. View

11.

Pauletti G, Godolphin W, Press M, Slamon D . Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996; 13(1):63-72. View

12.

Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz C, Dantis L . Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 1996; 14(3):737-44. DOI: 10.1200/JCO.1996.14.3.737. View

13.

Seidman A, Fornier M, Esteva F, Tan L, Kaptain S, Bach A . Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol. 2001; 19(10):2587-95. DOI: 10.1200/JCO.2001.19.10.2587. View

14.

Kakar S, Puangsuvan N, Stevens J, Serenas R, Mangan G, Sahai S . Comparison of PathVysion and INFORM fluorescence in situ hybridization kits for assessment of HER-2/neu status in breast carcinoma. Mol Diagn. 2000; 5(3):193-7. DOI: 10.1054/modi.2000.16689. View

15.

OMalley F, Parkes R, Latta E, Tjan S, Zadro T, Mueller R . Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry. Am J Clin Pathol. 2001; 115(4):504-11. DOI: 10.1309/VP4W-5C55-7M09-6TX3. View

16.

Tubbs R, Pettay J, Roche P, Stoler M, Jenkins R, Myles J . Concomitant oncoprotein detection with fluorescence in situ hybridization (CODFISH): a fluorescence-based assay enabling simultaneous visualization of gene amplification and encoded protein expression. J Mol Diagn. 2001; 2(2):78-83. PMC: 1906899. DOI: 10.1016/S1525-1578(10)60620-4. View

17.

Kallioniemi O, Holli K, Visakorpi T, Koivula T, Helin H, Isola J . Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer. 1991; 49(5):650-5. DOI: 10.1002/ijc.2910490504. View

18.

Tanner M, Gancberg D, Di Leo A, Larsimont D, Rouas G, Piccart M . Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol. 2000; 157(5):1467-72. PMC: 1885742. DOI: 10.1016/S0002-9440(10)64785-2. View

19.

Thor A, Berry D, Budman D, Muss H, Kute T, Henderson I . erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1998; 90(18):1346-60. DOI: 10.1093/jnci/90.18.1346. View

20.

Press M, Bernstein L, Thomas P, Meisner L, Zhou J, Ma Y . HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997; 15(8):2894-904. DOI: 10.1200/JCO.1997.15.8.2894. View